BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET to discuss GBS phase 3 data. Conference Call and Webcast InformationThe live webcast and replay may be accessed by visiting Annexon’s website here. The dial-in nu ...

A downtrend has been apparent in Annexon, Inc. (ANNX) lately with too much selling pressure. The stock has declined 5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spo ...

BRISBANE, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the new ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ANNX The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT ...

Exhibit 99.1 Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the First Targeted Treatment for GBS New Phase 2 Data Showing Neuroprotection of Vision and Vision-Associated Structures by ANX007 in Geographic Atrophy (GA) Presented at ARVO 2024; Initiation of Pivotal Phase 3 ANX007 ARC ...

ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings ANX007 protected key retinal structures important for vision: significant reduction of photoreceptor loss and meaningful slowing of lesion growth measured by retinal pigment epithelium (RPE) loss in the fovea C1q blockade protected photoreceptor synapses and preserved retinal function in preclinical model, supporting the mechanistic understanding of ANX007 in preserving syna ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Annexon, Inc. (ANNX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Annexon, Inc. is a member of the Medical sector. This group includes 1051 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 differ ...

BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on April 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the ...

公司任命 - Turnstone Biologics Corp.宣布任命William Waddill为公司董事会成员[1] - William Waddill在生物技术领域拥有三十多年的财务和运营经验[2] 公司业务 - Turnstone Biologics是一家临床阶段的生物技术公司，致力于开发治疗实体肿瘤的新方法[5]

公司股价表现 - Annexon, Inc. (ANNX) 最近的股价为 $6.17，较前一交易日收盘价下跌了 -0.96% [1] - 公司股价在过去一个月上涨了 35.73%，超过了医疗行业的下跌幅度 3.76% 和标普500指数的涨幅 1.78% [2] 财报预测 - 预计 Annexon, Inc. 即将发布的财报将受到投资者的极大关注，预计公司将报告每股收益为 -$0.32，较去年同期增长了 38.46% [3] - 分析师对 Annexon, Inc. 的最新预测修订值得投资者关注，这些修订通常反映了短期业务趋势的变化 [4]